Related Experiment Video
Updated: Aug 7, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Biosimilar Nivolumab-Based Combination Therapy in Advanced Oral Cavity Squamous Cell Carcinoma: A Real-World Case
Santhosh Meedimale1, Soumya S Panda2, Vipulkumar Thummar3
1Department of Medical Oncology, Omega Hospitals, Karimnagar, IND.
Abstract:
Squamous cell carcinomas of the head and neck (SCCHN) belongs to a biologically aggressive group of malignancies. The salvage options, after failure of the platinum-based therapy and immune checkpoint inhibitors (ICIs), are usually very limited. The regimen comprising oral methotrexate, erlotinib, and celecoxib (OMCT) has been explored as a well-tolerated, low-dose management option. We present through the case series the clinical outcomes of patients who had recurrent, refractory, or locally advanced SCCHN treated with OMCT in combination with low-dose nivolumab for translatable evidence.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

